Australia's Atomo Diagnostics jumps on plans to enter North America
28/07/2020 05:45
** Shares of Atomo Diagnostics Ltd AT1.AX rise as much as
14.9% to A$0.425, their highest since May 11
** Rapid blood test company signs agreement with U.S-based
Access Bio to enter North American market
** Atomo to supply its integrated rapid diagnostic test
(RDT) devices to Access Bio for use with its rapid test strip
for detection of antibodies to COVID-19 urn:newsml:reuters.com:*:nASX1zbJtX
** Following regulatory authorisations and approvals,
co-branded products will be produced by Access Bio and launched
in the United States, Canada and Mexico
** Stock posts its biggest intraday percentage gain since
July 15
** More than 8.8 mln shares change hands, compared with the
30-day average volume of 2.7 mln shares
** As of last close, stock had fallen 5.1% since its ASX
debut on April 16
(Reporting by Nikhil Subba in Bengaluru)
((Nikhil.Subba.thomsonreuters.com@reuters.net))